Antibody Ingredients TRIZ Cases

HLA-I evolutionary divergence quantifies sequence differences to predict immunotherapy response, avoiding unnecessary treatments for non-responders.

Measures plasma protein concentrations to predict severe dengue, resolving the inability of current diagnostics to assess virulence early.

Engineered antibody binding the SEMA domain prevents c-Met dimerization, blocking cancer signals without chemotherapy.

Fully human antibody drug conjugates bind to the 24P4C12 protein to deliver cytotoxic payloads directly to tumor cells.

GPIbα-deficient mice enable production of monoclonal antibodies recognizing human and mouse receptors, resolving immune tolerance limits.

Targeted immunotherapy overcomes tumor resistance by binding specific glycan markers to eliminate malignant cells.

A human LIFR antigen binding protein developed using H2L2 transgenic mice and single B cell cloning to achieve high affinity.

Engineered linkers resolve stoichiometry and stability contradictions by enabling site-specific conjugation to reduce toxicity.

Mutant anti-human IgE antibodies with Fc portion mutations reduce anaphylaxis by lowering Fc gamma receptor binding.

CFH-binding antibodies recruit complement components to tumor cells, triggering direct cell lysis through targeted immune activation.

Binder-drug conjugates utilize peptide linkers cleaved by lysosomal enzymes to release cytotoxic agents within target cells.

A specific binding molecule targets galectin-3 protein with high affinity to enable precise monoclonal antibody development.

Humanizing single domain antibodies reduces immunogenicity while maintaining high affinity binding to PD-L1 and CD47 targets.

Antibodies engineered with histidine residues bind VISTA specifically at acidic pH, reducing off-target effects on circulating cells.

Defined anti-ILT4 antibody dosage ranges and schedules balance enhanced anti-tumor efficacy against increased immune stimulation risks.

MIC-binding antibodies neutralize circulating sMIC to restore NKG2D expression on immune cells, countering tumor-induced immune evasion.

Human anti-CD33 antibodies reduce CD33 activity to enhance anti-tumor immune responses, addressing limited efficacy in solid tumors and Alzheimer's disease.

Co-administering focal radiation and CD47 blockade overcomes radioprotection, enabling macrophage phagocytosis of resistant solid tumors.

A high-affinity anti-B7-H3 antibody uses optimized complementarity-determining regions to bind target antigens with sub-nanomolar precision.

Specific binding agents inhibit glycoprotein Ib alpha shedding, preventing platelet clearance and extending storage duration.

Thioether and peptide linker resists enzyme hydrolysis, reducing off-target toxicity in antibody-drug conjugates.

A dual phosphate-amino acid buffer system stabilizes liquid antibody formulations while maintaining low viscosity.

Segmenting therapeutic and diagnostic functions into non-cross-reactive antibodies increases the signal-to-background ratio for accurate tumor localization.

Compounds bind MHC class I molecules to block LILRB receptor interaction, activating immune cells beyond limited checkpoint inhibitor pathways.

Mutating CDR regions in synthetic phage libraries generates human anti-PD-1 antibodies with enhanced specificity to inhibit PD-L1 binding for cancer treatment.

Antibodies block KIR2DL5 binding to PVR, restoring NK cell cytotoxicity against cancer cells.

Continuous perfusion process yields purified pembrolizumab compositions with minimized methionine 105 oxidation levels.

Modified Fc region reduces internalization rate in B-CLL cells, preserving mean fluorescence intensity for effective T-cell cytotoxicity.

Small molecule integrin ligand mimetics replace toxic adjuvants by facilitating integrin-ligand interactions to enhance immune response priming.

Monoclonal antibodies bind human TIGIT to block inhibitory signaling, restoring NK cell cytotoxicity against tumors.

Engineered complementarity-determining regions boost CD38 binding specificity while preventing healthy tissue interaction.

Human anti-EpCAM IgG1 antibody recruits natural killer cells to eliminate tumor cells, addressing limited survival rates in metastatic breast cancer.

Modified Fc domains reduce off-target cell killing while maintaining tumor-specific T cell activation.

Antigen-binding proteins reprogram tumour-associated macrophages by inducing pro-inflammatory cytokine release without blocking HLA-G interactions.

Antibodies binding human PD-1 block PD-L1 and PD-L2 interaction, restoring T-cell activation against tumor immune evasion.

Specific binder molecules inhibit neutrophil elastase protease activity and cell uptake, addressing tumor proliferation and inflammatory conditions.

Bispecific single chain antibody targets conserved primate CD3 epitopes to unify preclinical testing and clinical therapy, reducing development time.

Anti-CD22 antibody-drug conjugates deliver cytotoxic payloads via site-specific cysteine conjugation to malignant B cells.

Antibodies with unique epitope binding profiles avoid red blood cell depletion while promoting macrophage-mediated phagocytosis of tumor cells.

Engineered anti-CD154 antibodies eliminate thrombogenic reactions by removing harmful Fc region interactions while maintaining therapeutic efficacy.

Targeting ZIP12 reduces intracellular labile zinc levels and prevents hypoxia-induced vascular remodeling in pulmonary hypertension.

Modifying antibody Fc regions eliminates Fc receptor binding, reducing systemic toxicity while maintaining high-affinity NKG2D activation.

Humanized bi-specific antibodies activate T cells via CD3 binding to eliminate murine immunogenicity and allergic reaction risks in cancer therapy.

Merging anti-KIR and anti-CTLA-4 antibodies into one formulation resolves the trade-off between treatment complexity and overall survival improvement.

Measuring B-type natriuretic peptide levels detects cardiovascular toxicity risks from DLL4 antagonists, enabling safer cancer treatment administration.